Financials in GBp. Standardized financial statements.
A compact view of how Ondine Biomedical Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | £2.65M | £2.05M | £1.20M | £638,000 | £2.57M | £1.79M | £464,000 | £373,000 | £412,000 | £1.53M |
| Revenue Growth? | +29.5% | +70.3% | +88.6% | -75.2% | +43.4% | +286.0% | +24.4% | -9.5% | -73.1% | 0.0% |
| Cost of Revenue? | £1.56M | £728,000 | £500,000 | £351,000 | £1.31M | £1.14M | £328,000 | £485,000 | £311,000 | £313,664 |
| Gross Profit? | £1.09M | £1.32M | £703,000 | £287,000 | £1.25M | £649,000 | £136,000 | -£112,000 | £101,000 | £1.22M |
| Gross Margin? | +41.2% | +64.5% | +58.4% | +45.0% | +48.8% | +36.2% | +29.3% | -30.0% | +24.5% | +79.5% |
| Operating Expenses? | £31.13M | £20.77M | £15.51M | £19.05M | £18.77M | £16.52M | £14.16M | £16.42M | £5.88M | £5.01M |
| Operating Income? | -£30.04M | -£19.44M | -£14.80M | -£18.76M | -£17.52M | -£15.87M | -£14.03M | -£16.53M | -£5.78M | -£4.18M |
| EBITDA? | -£29.45M | -£18.49M | -£13.79M | -£18.85M | -£48.36M | -£14.56M | -£12.59M | -£15.61M | -£5.45M | -£3.88M |
| Income Before Tax | -£29.59M | -£19.10M | -£14.41M | -£19.37M | -£50.09M | -£16.21M | -£13.99M | -£16.66M | -£6.43M | -£3.27M |
| Income Tax Expense | £0 | £0 | £0 | £0 | £0 | £0 | £0 | £0 | £0 | -£11,844 |
| Net Income? | -£29.59M | -£19.10M | -£14.41M | -£19.37M | -£50.09M | -£16.27M | -£13.98M | -£16.66M | -£6.43M | -£3.26M |
| EPS? | £-0.06 | £-0.07 | £-0.07 | £-0.10 | £-0.26 | £-0.08 | £-0.07 | £-0.09 | £-0.03 | £-0.02 |
| Diluted EPS? | £-0.06 | £-0.07 | £-0.07 | £-0.10 | £-0.26 | £-0.08 | £-0.07 | £-0.09 | £-0.03 | £-0.02 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality